Fig. 1From: Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trialProgression-free survival (PFS) by primary KIT mutational status in Study 1199. CI, confidence interval; HR, hazard ratio; ITT, intent-to-treatBack to article page